The complex etiology of multiple sclerosis

Biochemical Pharmacology

Volumn 74, Issue 9, 2007, Pages 1321-1329

  Winquist, Raymond J ^a   Kwong, Ann ^a   Ramachandran, Ravi ^a   Jain, Jugnu ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Autoimmune; Demyelination; EAE; Inflammation; Multiple sclerosis; Myelin

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA INTERFERON; BETA1A INTERFERON; CANNABINOID RECEPTOR AGONIST; FASUDIL; FINGOLIMOD; FUMADERM; FUMARIC ACID; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; GLATIRAMER; HLA DR ANTIGEN; HLA DR2 ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; LAQUINIMOD; LEFLUNOMIDE; MYELIN ASSOCIATED GLYCOPROTEIN; NATALIZUMAB; OLIGOCLONAL BAND; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PROTEOLIPID PROTEIN; RHO KINASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR BLOCKING AGENT; TERIFLUNOMIDE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL KV1.3 BLOCKING AGENT; WIN 2;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; BRADYCARDIA; CD4+ T LYMPHOCYTE; CELL CLONING; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 6P; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYONIC STEM CELL; GENE EXPRESSION; GENETIC LINKAGE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LINKAGE ANALYSIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; RELAPSE; REMYELINIZATION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBARACHNOID HEMORRHAGE; TH1 CELL; TH2 CELL;

EID: 34548837992     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.026     Document Type: Note

References (80)

1. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy; from pipe dreams to (therapeutic) pipelines. Proc Nat Acad Sci USA 101 (2004) 14599-14606
2. Bielekova B., Sung M.-H., Kadom N., Simon R., McFarland H., and Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 172 (2004) 3893-3904
3. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 354 (2006) 942-955
4. Quandt J.A., Baig M., Yao K., Kawamura K., Huh J., Ludwin S.K., et al. Unique clinical and pathological features in HLA-DRB1*0401-restricted MBP 111-129-specific humanized TCR transgenic mice. J Exp Med 200 (2004) 223-234
5. Pettinelli C.B., and McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement of Lyt 1 + 2-T lymphocytes. J Immunol 127 (1981) 1420-1423
6. Ludwin S.K. The pathogenesis of multiple sclerosis: relating human pathology to experimental studies. J Neuropathol Exp Neurol 65 (2006) 305-318
7. Yu M., Nishiyama A., Trapp B.D., and Tuohy V.K. Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 64 (1996) 91-100
8. National Multiple Sclerosis website, www.nationalmssociety.org/pdf/research/agents.pdf.
9. Rovaris M., Confavreux C., Furlan R., Kappos L., Comi G., and Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 5 (2006) 343-354
10. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47 (2000) 707-717
11. Barnett M.H., and Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55 (2004) 458-468
12. Chaudhuri A., and Behan P.O. Multiple sclerosis in not an autoimmune disease. Arch Neurol 61 (2004) 1610-1612
13. Vukusic S., and Confavreux C. Primary and secondary progressive multiple sclerosis. J Neurol Sci 206 (2003) 153-155
14. Hafler D.A. Multiple sclerosis. J Clin Invest 113 (2004) 788-794
15. Trotter J.L., Hickey W.F., van der Veen R.C., and Sulze L. Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. J Neuroimmunol 33 (1991) 55-62
16. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., and Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122 (1999) 2089-2100
17. van Noort J.M., Bajramovic J.J., Plomp A.C., and van Stipdonk M.J.B. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 105 (2000) 46-57
18. Vaknin-Dembinsky A., Balashov K., and Weiner H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 176 (2006) 7768-7774
19. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500-508
20. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2001) 1167-1175
21. Avasarala J.R., Cross A.H., and Trotter J.L. Oligoclonal band numbers as a marker for prognosis in multiple sclerosis. Arch Neurol 58 (2001) 2044-2045
22. Panitch H.S., Hirsch R.L., Schindler J., and Johnson K.P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37 (1987) 1097-1102
23. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 (2002) S3-S9
24. Stüve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59 (2006) 743-747
25. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P.A., LIbonati M., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348 (2003) 15-23
26. Compston A., and Sawcer S. Genetic analysis of multiple sclerosis. Curr Neurol Neurosci Rep 2 (2002) 259-266
27. Sadovnick A.D., Armstrong H., Rice G.P., Bulman D., Hashimoto L., Paty D.W., et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 33 (1993) 281-285
28. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 37 10 (2005) 1108-1112
29. Reich D., Patterson N., De Jager P.L., McDonald G.J., Waliszewska A., Tandon A., et al. A whole-genome admixture scan finds a candidate locus for multiple sclerosis susceptibility. Nat Genet 37 10 (2005) 1113-1118
30. Kammer A.R., and Ertl H.C.J. Rabies vaccines: from the past to the 21st century. Hybridoma Hybridomics 21 (2002) 123-127
31. Rivers T.M., Sprunt D.H., and Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Exp Med 58 (1933) 39-53
32. Karpus W.J., Kennedy K.J., Smith W.S., and Miller S.D. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide. J Neurosci Res 45 (1996) 410-423
33. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (2005) 1133-1141
34. Iglesias A., Bauer J., Litzenburger T., Schubart A., and Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36 (2001) 220-234
35. Ellmerich S., Mycko M., Takacs K., Waldner H., Wahid F.N., Boyton R.J., et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 174 (2005) 1938-1946
36. Somma P., Ristori G., Battistini L., Cannoni S., Borsellino G., Diamantini A., et al. Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis. J Leukocyte Biol 81 (2007) 696-710
37. Wang W.Z., Olsson T., Kostulas V., Hojeberg B., Ekre H.P., and Link H. Myelin antigen reactive T cells in cerebrovascular disease. Clin Exp Immunol 88 (1992) 157-162
38. Yu X., Gilden G.H., Ritchie A.M., Burgoon M.P., Keays K.M., and Owens G.P. Specificity of recombinant antibodies generated from multiple sclerosis cerebrospinal fluid probed with a random peptide library. J Neuroimmunol 172 (2006) 121-131
39. Katti M.K. Immunodiagnosis of tuberculous meningitis: rapid detection of mycobacterial antigens in cerebrospinal fluid by reverse passive hemagglutination assay and their characterization by Western blotting. FEMS Immunol Med Microbiol 31 (2001) 59-64
40. Imrell K., Landtblom A.M., Hillert J., and Masterman T. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 67 (2006) 1062-1064
41. Trapp B.D. Pathogenesis of multiple sclerosis: the eyes only see what the mind is prepared to comprehend. Ann Neurol 55 (2004) 455-457
42. Bø L., Vedeler C.A., Nyland H., Trapp B.D., and Mørk S.J. Intracortical multiple sclerosis lesions are not associated with lymphocyte infiltration. Mult Scler 9 (2003) 323-331
43. DeStefano N., Narayanan S., Francis S.J., Smith S., Mortilla M., Tartaglia M.C., et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol 59 (2002) 1565-1571
44. The Lenercept Multiple Sclerosis Study Group, and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS results of a randomized, placebo-controlled multicenter study. Neurology 53 (1999) 457-465
45. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-α. FASEB J 20 (2006) 670-682
46. Asakura K., and Rodriguez M. A unique population of circulating autoantibodies promotes central nervous system remyelination. Mult Scler 4 (1998) 217-221
47. Vanderlocht J., Hellings N., Hendriks J.J., Vandenabeele F., Moreels M., Buntinx M., et al. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J Neurosci Res 83 (2006) 763-774
48. Tepavcevic V., and Blakemore W.F. Glial grafting for demyelinating disease. Philos Trans R Soc Lond B Biol Sci 360 (2005) 1775-1795
49. Wandinger K.-P., Stürzebecher C.-S., Bielekova B., Detore G., Rosenwald A., Staudt L.M., et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 50 (2001) 349-357
50. Haines J.L., Terwedow H.A., Burgess K., Pericak-Vance M.A., Rimmler J.B., Martin E.R., et al. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum Mol Genet 7 (1998) 1229-1234
51. Dauvilliers Y., and Tafti M. Molecular genetics and treatment of narcolepsy. Ann Med 38 (2006) 252-262
52. van Baarsen L.G.M., van der Pouw Kraan T.C.T.M., Kragt J.J., Baggen J.M.C., Rustenburg F., Hooper T., et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 7 (2006) 522-531
53. Mameli G., Astone V., Arru G., Marconi S., Lovato L., and Serra C. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6. J Gen Virol 88 (2007) 264-274
54. Álvarez-Lafuente R., De las Heras V., Bartolomé M., Picazo J.J., and Arroyo R. Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection. Arch Neurol 61 (2004) 1523-1527
55. Stratton C.W., and Wheldon D.B. Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae. Trends Microbiol 14 (2006) 474-479
56. Scarisbrick I.A., and Rodriguez M. Hit-hit and hit-run: viruses in the playing field of multiple sclerosis. Curr Neurol Neurosci Rep 3 (2003) 265-271
57. Evans C.F., Horwitz M.S., Hobbs M.V., and Oldstone M.B. Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease. J Exp Med 184 (1996) 2371-2384
58. Christensen T. The role of EBV in MS pathogenesis. Int MS J 13 (2006) 52-57
59. Runström A., Leanderson T., Ohlsson L., and Axelsson B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice. J Neuroimmunol 173 (2006) 69-78
60. Polman C., Barkhof F., Sandberg-Wollheim M., Linde A., Nordle O., Nederman T., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64 (2005) 987-991
61. Mandala S., Hajdu R., Bergstrom J., Quackenbush E., Xie J., Milligan J., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296 (2002) 346-349
62. Kappos L., Antel J., Comi G., Montalban X., O'Connor P., Polman C.H., et al. Oral Fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 (2006) 1124-1140
63. Doggrell S.A. Is fingolimod an advancement in the treatment of multiple sclerosis?. Expert Opin Pharmacother 8 (2007) 383-386
64. Schimrigk S., Brune N., Hellwig K., Lukas C., Bellenberg B., Rieks M., et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13 (2006) 604-610
65. Lehmann J.C., Listopad J.J., Rentzsch C.U., Igney F.H., von Bonin A., Hennekes H.H., et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 127 (2007) 835-845
66. Zevda M., Poglitsch M., Geveregger R., Smolen J.S., Zlabinger G.J., Horl W.H., et al. Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum 52 (2005) 2730-2739
67. Chong A.S., Zeng H., Knight D.A., Shen J., Meister G.T., Williams J.W., et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 6 (2006) 69-75
68. O'Connor P.W., Freedman M.S., Bar-Or A., Rice G.P., Confavreux C., Paty D.W., et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66 (2006) 894-900
69. Wade D.T., Makela P.M., House H., Bateman C., and Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12 (2006) 639-645
70. Onaivi E.S., Leonard C.M., Ishiguro H., Zhang P.W., Lin Z., Akinshola B.E., et al. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 66 (2002) 307-344
71. 2 receptor. Biochem Pharmacol 72 (2006) 1697-1706
72. Ni X., Geller E.B., Eppihimer M.J., Eisenstein T.K., Adler M.W., and Tuma R.F. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10 (2004) 158-164
73. Mueller B.K., Mack H., and Teusch N. Rho kinase, a promising drug target for neurological disorders. Nature Rev 4 (2005) 387-398
74. Sun X., Minohara M., Kikuchi H., Ishizu T., Tanaka M., Piao H., et al. The selective Rho-kinase inhibitor fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 180 (2006) 126-134
75. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67 (2005) 1369-1381
76. Schmitz A., Sankaranarayanan A., Azam P., Schmidt-Lassen K., Homerick D., Hänsel W., et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune disease. Mol Pharmacol 68 (2005) 1254-1270
77. Fordyce C.B., Jagasia R., Zhu X., and Schlichter L.C. Microglia Kv1.3 channels contribute to their ability to kill neurons. J Neurosci 25 (2005) 7139-7149
78. Metz I., Lucchinetti C.F., Openshaw H., Garcia-Merino A., Lassmann H., Freedman M.S., et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain 130 (2007) 1254-1262
79. Karussis D.M., Vourka-Karussis U., Lehmann D., Ovadia H., Mizrachi-Koll R., Ben-Nun A., et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest 92 (1993) 765-772
80. Nistor G.I., Totoiu M.O., Haque N., Carpenter M.K., and Keirstead H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49 (2005) 385-396